MediWound to Participate in Upcoming March Investment Conferences
MediWound Ltd. (Nasdaq: MDWD) has announced its participation in two upcoming virtual investor conferences in March 2021. The company will present at the Cowen 41st Annual Health Care Conference on March 2 at 9:10 am ET, and at the Oppenheimer 31st Annual Healthcare Conference on March 16 at 1:10 pm ET. Investors can access live webcasts of both events on the company's website, along with replays available for 30 days. MediWound focuses on innovative bio-therapeutic solutions for tissue repair, highlighted by its product NexoBrid, currently marketed in the EU and a BLA submitted for the U.S.
- None.
- None.
YAVNE, Israel, Feb. 25, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will present at the following virtual investor conferences in March 2021:
| Cowen 41st Annual Health Care Conference | |
| Date: | Tuesday, March 2 |
| Time: | 9:10 am ET |
| Oppenheimer 31st Annual Healthcare Conference | |
| Date: | Tuesday, March 16 |
| Time: | 1:10 pm ET |
A live webcast of each event will be available on the Events page of the Investors section of the Company's website: www.mediwound.com. A replay of each webcast will be available on the Company’s website for approximately 30 days.
About MediWound Ltd.
MediWound is a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Our strategy is centered around our validated enzymatic platform technology, focused on next-generation bio-active therapies for burn and wound care and biological medicinal products for tissue repair.
NexoBrid®, our first commercialized biological product for non-surgical and rapid eschar removal of deep, partial and full-thickness thermal burns without harming viable tissue, is currently marketed in the European Union and other International markets. On June 29, 2020, a biologics license application (BLA) was submitted to the U.S. FDA and was assigned a Prescription Drug User Fee Act (PDUFA) target date of June 29, 2021. NexoBrid is supported by U.S. Biomedical Advanced Research and Development Authority (BARDA).
EscharEx®, our next-generation bioactive topical therapeutic under development in the U.S. for debridement of chronic and hard to heal wounds. In two Phase 2 studies, EscharEx was well-tolerated and has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications.
MediWound’s third innovative product candidate, MWPC005, is a topical drug under development for the treatment of non-melanoma skin cancer.
Committed to innovation, we are dedicated to improving quality of care and patient lives. For more information, please visit www.mediwound.com.
| Contacts: | |
| Boaz Gur-Lavie | Jeremy Feffer |
| Chief Financial Officer | Managing Director, LifeSci Advisors |
| MediWound Ltd. | 212-915-2568 |
| ir@mediwound.com | jeremy@lifesciadvisors.com |
FAQ
What investor conferences will MediWound (MDWD) present at in March 2021?
Where can I watch the MediWound (MDWD) investor conference presentations?
What is NexoBrid and its significance for MediWound (MDWD)?
When was the BLA for NexoBrid submitted and what is its target date?
What are the developments regarding EscharEx by MediWound (MDWD)?
